Tesamorelin Dosage Chart: One Approved Indication, One Population

What an approved label adds to the arithmetic

Every reconstitution calculation on this site is exact: labelled mass divided by diluent volume gives concentration, and volume drawn times concentration gives the amount in the syringe. The arithmetic is never the weak link.

The weak link is the target. For an unapproved compound there is no established quantity for the calculation to land on, so the exactness is decorative. Here there is one, because a regulator reviewed a trial programme and authorised specific quantities.

There is a second gain. An approved product carries a labelled mass somebody is accountable for, so the numerator in the calculation is verified rather than asserted. Material sold as a research chemical does not, which is why the same arithmetic on a research vial inherits whatever error the label carries.

The indication is one line, and it is narrow

The approved indication reads: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

The same section carries a limitation of use stating that long-term cardiovascular safety has not been established, and directing prescribers to weigh risk and benefit in patients who have not had a reduction in visceral adipose tissue.

What the label fixes	Value
Approval	FDA, BLA 022505 (Theratechnologies)
Marketed as	EGRIFTA, latterly EGRIFTA SV
Population	HIV-infected adults with lipodystrophy
Outcome	Reduction of excess abdominal fat
Stated limitation	Long-term cardiovascular safety not established
Form	Prescription powder for reconstitution

Roughly 24 studies are registered under the name on ClinicalTrials.gov.

Where a chart stops being a restatement

A tesamorelin dosage chart that restates approved quantities alongside the indication they were approved for is reporting. The provenance is genuine and better than anything available for the unapproved compounds covered elsewhere on this site.

A chart that carries the same quantities with no population attached has changed what it is claiming without changing a single digit. The figures were established in HIV-associated lipodystrophy for reduction of visceral fat. Applied to general body composition they become an extrapolation, and extrapolation in a table is indistinguishable from reporting unless the table says so.

That is the one thing to check on any chart for this compound, and it is not a number.

Frequently Asked Questions

Is tesamorelin an approved drug?expand_more

Yes. It is approved by the FDA and marketed as EGRIFTA, latterly EGRIFTA SV, under BLA 022505 held by Theratechnologies.

What is the approved indication?expand_more

Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label also states that long-term cardiovascular safety has not been established.

Does an approved label make the reconstitution arithmetic more reliable?expand_more

It makes the inputs more reliable. The arithmetic is exact either way, but an approved product carries a labelled mass somebody is accountable for, where a research chemical carries a seller's claim.

Can approved quantities be applied to a different goal?expand_more

Not without leaving what the authorisation covers. The quantities were established in one population for one endpoint, and the approval is attached to that pairing.

How much research exists?expand_more

Around 24 studies are registered on ClinicalTrials.gov under the name, which is substantial relative to most compounds covered here.

Worked Examples — Related Compound Protocols

Apply this guide to real protocols. Each linked page includes a live reconstitution calculator and titration schedule.

Sermorelin dosage protocol

Sermorelin (formerly Geref) is a synthetic 29-amino-acid peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH) and was the first commercially marketed GHRH analogue. The biologically active region of native 44-amino-acid GHRH resides in the first 29 residues, making sermorelin a full agonist at the GHRH receptor. Sermorelin received FDA approval in 1990 as a diagnostic agent for GH deficiency and in 1997 for treatment of paediatric idiopathic GH deficiency under the brand name Geref (Serono). Serono voluntarily discontinued commercial production in 2008 due to manufacturing process difficulties, not safety concerns. The Geref International Study Group multicentre trial (J Pediatr 1996) showed that 30 mcg/kg/day subcutaneous sermorelin at bedtime increased growth velocity from 4.1 to 8.0 cm/year at 6 months in 110 GH-deficient prepubertal children. Although it no longer holds an active FDA-approved product, sermorelin is on the FDA 503A bulks list and remains widely used in compounding pharmacy. Adult research dosing is 200-500 mcg subcutaneously nightly.

Open protocolarrow_forward

BPC-157 dosage protocol

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a larger Body Protection Compound originally isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s [1][2]. Across more than 30 years of preclinical work, BPC-157 has been shown to accelerate the healing of tendon, ligament, muscle, bone, skin, gastrointestinal tract, and cornea through pro-angiogenic mechanisms involving VEGF receptor 2 (VEGFR2) activation, nitric oxide synthase upregulation through the Akt-eNOS axis, ERK1/2 signaling, and modulation of the dopaminergic and serotonergic systems [3][4]. Chang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 promotes tendon healing by enhancing tendon outgrowth, cell survival, and migration in tendon fibroblast cultures, and that it upregulates growth hormone receptor expression in those cells [5][6]. BPC-157 is not FDA approved and remains a research peptide. Typical research dosing is 250 to 500 mcg/day subcutaneously, with cycles of 4 to 8 weeks.

Open protocolarrow_forward

MOTS-C dosage protocol

MOTS-c (mitochondrial open reading frame of the twelve-S ribosomal RNA type c) is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome and discovered by Changhan Lee, Pinchas Cohen, and colleagues at USC. Unlike all other known signaling peptides, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA, making it the founding member of a class of mitochondrial-derived peptides. In the seminal Cell Metabolism 2015 paper, MOTS-c was shown to enhance glucose utilization, activate AMPK, prevent age-dependent and diet-induced insulin resistance, and reduce diet-induced obesity in mice. Subsequent work demonstrated that exercise induces MOTS-c expression and that late-life MOTS-c treatment increases physical capacity. Research subcutaneous dosing typically uses 5–10 mg two or three times per week. MOTS-c is not FDA approved; an investigational MOTS-c analog (CB4211) for non-alcoholic fatty liver disease was studied in Phase Ib trials.

Open protocolarrow_forward

References & Citations

[1]
FDA Drugs@FDA. EGRIFTA / EGRIFTA SV (tesamorelin), BLA 022505, Theratechnologies. Prescription powder; indication and limitations of use as stated on the approved label.View source →
[2]
ClinicalTrials.gov. Studies registered under the term tesamorelin.View source →